![]() |
Name |
Nigerasperone
|
Molecular Formula | C31H26O11 | |
IUPAC Name* |
7-(2,5-dihydroxy-6,8-dimethoxy-2-methyl-4-oxo-3H-benzo[g]chromen-10-yl)-4,5-dihydroxy-6-methoxy-2-methylbenzo[g]chromen-8-one
|
|
SMILES |
COc1cc(OC)c2c(O)c3c(c(-c4c(OC)c5c(O)c6c(O)cc(C)oc6cc5cc4=O)c2c1)OC(C)(O)CC3=O
|
|
InChI |
InChI=1S/C31H26O11/c1-12-6-16(32)24-20(41-12)8-13-7-17(33)25(29(40-5)21(13)27(24)35)23-15-9-14(38-3)10-19(39-4)22(15)28(36)26-18(34)11-31(2,37)42-30(23)26/h6-10,32,35-37H,11H2,1-5H3/t31-/m1/s1
|
|
InChIKey |
PIXNRLCOGGHRMO-WJOKGBTCSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 574.54 | ALogp: | 4.9 |
HBD: | 4 | HBA: | 11 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 165.1 | Aromatic Rings: | 6 |
Heavy Atoms: | 42 | QED Weighted: | 0.207 |
Caco-2 Permeability: | -5.3 | MDCK Permeability: | 0.00001580 |
Pgp-inhibitor: | 0.977 | Pgp-substrate: | 0.007 |
Human Intestinal Absorption (HIA): | 0.647 | 20% Bioavailability (F20%): | 0.001 |
30% Bioavailability (F30%): | 0.058 |
Blood-Brain-Barrier Penetration (BBB): | 0.001 | Plasma Protein Binding (PPB): | 76.43% |
Volume Distribution (VD): | 0.572 | Fu: | 29.81% |
CYP1A2-inhibitor: | 0.278 | CYP1A2-substrate: | 0.97 |
CYP2C19-inhibitor: | 0.106 | CYP2C19-substrate: | 0.17 |
CYP2C9-inhibitor: | 0.634 | CYP2C9-substrate: | 0.832 |
CYP2D6-inhibitor: | 0.019 | CYP2D6-substrate: | 0.311 |
CYP3A4-inhibitor: | 0.122 | CYP3A4-substrate: | 0.158 |
Clearance (CL): | 2.588 | Half-life (T1/2): | 0.126 |
hERG Blockers: | 0.018 | Human Hepatotoxicity (H-HT): | 0.083 |
Drug-inuced Liver Injury (DILI): | 0.971 | AMES Toxicity: | 0.144 |
Rat Oral Acute Toxicity: | 0.05 | Maximum Recommended Daily Dose: | 0.482 |
Skin Sensitization: | 0.2 | Carcinogencity: | 0.014 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.249 |
Respiratory Toxicity: | 0.061 |